Program News
News and stories about members of the UNC Lineberger Molecular Therapeutics Research Program
-
Fired up for RNA
Chad Pecot, MD, is revolutionizing RNA therapies for cancer through his company EnFuego Therapeutics and the new UNC RNA Discovery Center.
-
UNC Lineberger members recognized for highly cited research
Nine UNC Lineberger members wrote some of the most influential scientific papers in the past decade, according to an independent analysis of research publications.
-
UNC scientist’s work contributes to Nobel Prize in Chemistry
The 2024 Nobel Prize in Chemistry recognized groundbreaking work in computational protein design and protein structure prediction. Brian Kuhlman, PhD, made significant contributions to this work while a postdoctoral researcher in the Baker lab.
-
A call to bridge the gap in cancer clinical trial funding
In a Journal of Clinical Oncology editorial, Yara Abdou, MD, and Norman E. Sharpless, MD, share their concerns about a growing reliance on industry-sponsored cancer clinical trials in the U.S.
-
Rushing receives $3.9 million NCI grant to create the Human Cancer Metabolome Atlas
Blake Rushing, PhD, will support the development of the Human Cancer Metabolome Atlas. The project aims to map the complex metabolic processes that drive cancer’s progression and resistance to treatment.
-
New compound shows promise in targeting cancer-linked protein
Lindsey James, PhD, and colleagues have developed a promising new compound that selectively and effectively breaks down a protein linked to various cancers, including multiple myeloma and prostate cancer.
-
UNC Lineberger provides $1.3 million in developmental research grants
More than $1.3 million in UNC Lineberger developmental research grants were awarded to 13 faculty members and one postdoctoral trainee this spring.
-
NIH Director’s blog features pancreatic cancer research led by Der and Cox
NIH Director Monica Bertagnolli, MD, wrote about research led by UNC Lineberger’s Channing Der, PhD, and Adrienne Cox, PhD, that provided the most comprehensive molecular portrait of the workings of KRAS.
-
UNC RNA Discovery Center retreat further builds community, highlight possibilities
The UNC RNA Discovery Center held its inaugural retreat to bring together its members and trainees to present and discuss RNA science being conducted across UNC-Chapel Hill and beyond.
-
Scientific symposium highlights latest developments in pancreatic cancer research
UNC Lineberger’s 47th annual scientific symposium featured 17 presentations from faculty at UNC Lineberger and institutions across the United States.
-
Molecular pathway that impacts pancreatic cancer progression and response to treatment detailed
UNC Lineberger researchers have established the most comprehensive molecular portrait of the workings of KRAS, a key cancer-causing gene, and how its activities impact pancreatic cancer outcomes.
-
UNC researchers to present at American Society of Clinical Oncology annual meeting
UNC and UNC Lineberger researchers and trainees will be presenting talks and participating in scientific and educational panels and discussions on the latest cancer research at the ASCO Annual Meeting.
-
A few minutes with Siddharth Sheth, DO, MPH
For Siddharth Sheth, DO, MPH, he knew UNC was the place for him when he pursued his first faculty position in medicine. However, it wasn’t just UNC that shaped his medical career. When Sheth’s mom was diagnosed with cancer and later relapsed, he knew oncology was the right path for him.
-
Newly engineered molecule bypasses toxicity previously found in key cancer-fighting pathway
UNC Lineberger researchers have developed a molecule that is much more effective than a previously identified molecule at activating a biological pathway and spurring a strong anti-cancer immune response in preclinical studies.
-
Yeh, Johnson awarded five-year, $3.2 million research grant from NCI
The grant will support the first metastatic pancreatic cancer trial in the country to evaluate whether selecting treatment by tumor subtype will help patients match to more effective first-line therapies.